Free accessResearch articleFirst published online 1998-4
In vitro Anti-Human Immunodeficiency Virus and Anti-Hepatitis B Virus Activities and Pharmacokinetic Properties of Heterodinucleoside Phosphates Containing AZT or ddC
In vitro activities, against human immunodeficiency virus (HIV)- and hepatitis B virus (HBV)-infected cells, of four amphiphilic heterodinucleoside phosphates containing 3′-azido-2′,3′-dideoxythymidine (AZT) or 2′,3′-dideoxycytidine (ddC) as antiviral monomers were evaluated. The four compounds were N4-hexadecyl-2′-deoxyribocytidylyl-(3′→5′)-3′-azido-2′,3′-deoxythymidine (N4-hxddC-AZT), N4-palmitoyl-2′-deoxyribocytidylyl-(3′→5′)-3′-azido-2′,3′-deoxythymidine (N4-pamdC-AZT), N4-hexadecyl-2′-deoxycytidylyl-(3′→5′)-2′,3′-dideoxycytidine (N4-hxddC-ddC) and 2′-deoxythymidylyl-(3′→5′)-N4-palmitoyl-2′,3′-dideoxycytidine (dT-N4-pamddC). All four dimers were active against HIV, dT-N4-pamddC being the most active and least toxic. dT-N4-pamddC also exhibited strong antiviral effects against a panel of eight AZT-resistant HIV strains. The ddC-containing heterodimers incorporated in liposomes additionally inhibited HBV replication by 50–80% in HepG2 2.2.15 cells. AZT and the AZT-containing dimers were ineffective. Differences in pharmacokinetic properties between the antiviral monomers and the heterodimers were evaluated using liposomal formulations of3H-labelled AZT heterodimers as model compounds. The cellular distribution of AZT in H9 cells was predominantly cytoplasmic, whereas the amphiphilic dimers were distributed more evenly throughout the cytoplasm, nuclear membranes and microsomes. Blood levels of the heterodimers decreased at a rate two- to threefold slower than AZT and the areas-under-the-curves were five- to sevenfold higher for N4-pamdC-AZT and N4-hxddC-AZT, respectively. Compared to AZT, the peak levels of the dimers were three to four times higher in blood and five to six times higher in the liver. Analysis of blood samples showed that 34% of N4-pamdC-AZT was metabolized to AZT, whereas only 9% of N4-hxddC-AZT released AZT. Considering the antiviral potency and the favourable pharmacokinetic properties of the heterodimers, these compounds merit further exploration as antiviral drugs.
Aoki-SeiSO'BrienMCFordHFujiiHGilbertDACooneyDAJohnsDGBroderS & MitsuyaH (1991) In vitro inhibition of hepatitis B virus replication by 2′,3′-dideoxyguanosine, 2′,3′-dideoxyinosine, and 3′-azido-2′,3′-dideoxythymidine in 2.2.15 (PR) cells. Journal of Infectious Diseases164:843–851.
2.
AhluwaliaGSGaoWYMitsuyaH & JohnsDG (1996) 2′,3′-Didehydro-3′-deoxythymidine: regulation of its metabolic activation by modulators of thymidine-5′-triphosphate biosynthesis. Molecular Pharmacology50:160–165.
3.
BalzariniJWedgwoodOKruiningJPelemansHHeijtinkRDe ClercqE & McGuiganC (1996) Anti-HIV and anti-HBV activity and resistance profile of 2′,3′-dideoxy-3′-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109. Biochemical & Biophysical Research Communications225:363–369.
4.
BenhamouYKatlamaCLunelFCoutellierADohinEHammNTubianaRHersonSPoynardT & OpolonP (1996) Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Annals of Internal Medicine125:705–712.
5.
ChisariFV & FerrariC (1995) Hepatitis B virus immunopathology. Springer Seminars in Immunopathology17:261–281.
6.
DoongSLTsaiCHSchinaziRFLiottaDC & ChengYC (1991) Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proceedings of the National Academy of Sciences, USA88:8495–8499.
7.
DusserreNLessardCPaquetteNPerronSPoulinLTremblayMBeauchampDDesormeauxA & BergeronMG (1995) Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution and pharmacokinetics. AIDS9:833–841.
8.
GallianPDe LamballerieXLehucherMPDhiverC & RavauxI (1996) Absent inhibition of hepatitis B virus replication by azidothymidine in patients chronically coinfected by HIV-1 and HBV. New Microbiologist19:167–169.
9.
GoodSSReynoldsDJ & de MirandaP (1988) Simultaneous quantification of zidovudine and its glucuronide in serum by high-performance liquid chromatography. Journal of Chromatography431:123–133.
10.
HopeMJBallyMBWebbG & CullisPR (1985) Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochimica et Biophysica Acta812:55–65.
11.
HorberDHOttigerCSchottH & SchwendenerRA (1995) Pharmacokinetic properties and interactions with blood components of N4-1-β-d-arabinofuranosylcytosine (NHAC) incorporated into liposomes. Journal of Pharmacy and Pharmacology47:282–288.
12.
HostetlerKYKorbaBESridharCN & GardnerMF (1994) Antiviral activity of phosphatidyl-dideoxycytidine in hepatitis B-infected cells and enhanced hepatic uptake in mice. Antiviral Research24:59–67.
13.
KorbaBE & GerinJL (1992) Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Research19:55–70.
14.
KorbaBE (1996) In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Research29:49–51.
15.
KriseJP & StellaVJ (1996) Prodrugs of phosphates, phosphonates, and phosphinates. Advances in Drug Delivery Reviews19:287–310.
16.
LocarniniSACiviticoGM & NewboldJE (1996) Hepatitis B: new approaches for antiviral chemotherapy. Antiviral Chemistry & Chemotherapy7:53–64.
17.
MosmannT (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. Journal of Immunological Methods65:55–63.
18.
NowakMABonhoefferSHillAMBoehmeRThomasHC & McDadeH (1996) Viral dynamics in hepatitis B virus infection. Proceedings of the National Academy of Sciences, USA93:4398–4402.
19.
SchinaziRFGosselinGFarajAKorbaBELiottaDCChuCKMatheCImbachJL & SommadossiJP (1994) Pure nucleoside enantiomers of beta-2′,3′-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro. Antimicrobial Agents & Chemotherapy38:2172–2174.
20.
SchottHHäusslerMPGowlandPHorberH & SchwendenerRA (1994) Synthesis, characterization and some properties of amphiphilic dinucleoside phosphate derivatives of 3′-azido-2′,3′-dideoxythymidine (AZT). Antiviral Chemistry & Chemotherapy5:387–394.
21.
SchottHHäusslerMPGowlandPBenderAvon BriesenH & SchwendenerRA (1995) Synthesis, and antiviral properties in vitro of amphiphilic dinucleoside phosphate derivatives of 2′,3′-dideoxycyticine (ddC). Antiviral Chemistry & Chemotherapy6:320–326.
22.
SchwendenerRAHorberDHGowlandPZahnerRSchertlerA & SchottH (1994) New lipophilic acyl/alkyl dinucleoside phosphates as derivatives of 3′-azido-3′-deoxythymidine: inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens. Antiviral Research24:79–93.
23.
SellsMAChenML & AcsG (1987) Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proceedings of the National Academy of Sciences, USA84:1005–1009.
24.
SeveriniALiuXYWilsonJSTyrrellDYWilsonJS & TyrrellDL (1995) Mechanism of inhibition of duck hepatitis B virus polymerase by (–)-β-l-(–)-β-l-2′,3′-dideoxy-3′-thiacytidine. Antimicrobial Agents & Chemotherapy39:1430–1435.
25.
SharmaAPOllapallyAP & LeeHJ (1993) Synthesis and anti-HIV activity of prodrugs of azidothymidine. Antiviral Chemistry & Chemotherapy4:93–96.
26.
ShawT & LocarniniSA (1995) Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Liver15:169–184.
27.
UedaTNakamuraTKagawaKUchidaMSasadaM & UchinoH (1983) Intracellular distribution of N4-behenoyl-1-β-d-arabinofuranosylcytosine in blood cells. Gann74:445–451.
28.
WeislowOWKiserRFineDBaderJShoemakerRH & BoydMR (1989) New soluble-formazan assay for HIV-1 cythopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. Journal of the National Cancer Institute81:577–586.
29.
XieHVoronkovMLiottaDCKorbaBASchinaziRFRichmanDD & HostetlerKY. (1995) Phosphatidyl-2′,3′-dideoxy-3′-thiacytidine: synthesis and antiviral activity in hepatitis B-and HIV-1-infected cells. Antiviral Research28:113–120.
30.
ZimmermannTPMahonyWB & PrusKL (1987) 3′-Azido-3′-deoxythymidine. Journal of Biological Chemistry262:5748–5754.